CambridgeRegulators approved the first drug for spinal muscular atrophy’s muscle loss.
Existing drugs for the disorder keep motor neurons alive but leave the muscle itself unrepaired.
Isembyld blocks myostatin, the protein that brakes muscle growth, unlike drugs that target the SMN2 gene.
The company has not disclosed a price, leaving affordability outside rich countries unclear.
How each outlet framed it
- STAT
- highlights clinical trial showing motor skill improvement vs placebo decline, breakthrough after decades of failed myostatin inhibition
Sources: STAT